Peptides
Glutathione
Also called GSH · L-γ-glutamylcysteinylglycine
People use glutathione products for brighter-looking skin, antioxidant support and a general “detox” effect. Oral supplements can raise measured glutathione stores, but that is not the same as proving more energy or a visible cosmetic change. Injections add product-quality and procedure risks without making the promised benefit automatic.
Dosage & duration
Published oral supplementation study · healthy adults
Six-month body-store trial
Published example · product-specific- Dose
- 250 mg or 1,000 mg total daily in separate groups
- How often
- Daily, oral
- How long
- 6 months
These were two study arms, not a suggested escalation range. The outcome was glutathione stores, not a cosmetic injection course.
Sources: 1
The existing oral research row and this guide refer to the same trial. Do not convert its amount to an IM or IV schedule.
The practical difference
Does an injection mean a better result?
People seek brighter-looking skin or antioxidant support. A different delivery route does not automatically deliver a more useful benefit.
| What the evidence says | Oral supplements | Injections |
|---|---|---|
| Finding | Measured body stores can rise | One IV combination study found limited, fading skin-tone change |
| What it does not prove | More energy or a visible cosmetic benefit | A lasting result from pure glutathione |
| Product distinction | An ingredient suitable for a supplement | Requires injectable quality; procedure risks also matter |
Why do people choose it?
Skin appearance and antioxidant support are the main attractions. The body already uses glutathione in its protective chemistry, but adding more does not establish a broad “detox” result. A useful goal should say what changes: a specific skin concern, a laboratory measure or day-to-day function.
Oral supplements versus injections
A placebo-controlled oral trial showed that body stores can rise over months. That corrects the blanket claim that oral glutathione never works, but does not show it delivers the same outcome as an injection. Conversely, bypassing the gut does not automatically make an injection more useful.
What about skin lightening?
The reviewed IV study used a combination product and found limited, fading improvement. It cannot justify a promise of lasting skin-tone change from pure glutathione. A cosmetic result also does not establish better health.
Product quality matters
FDA has described adverse events linked to endotoxin contamination when supplement-grade glutathione was used to compound injections. A capsule ingredient and a sterile injectable ingredient are not interchangeable. The relative timing plot cannot assess sterility, purity or the safety of an infusion.
Dose references and context Existing reported protocols; not personal dosing instructions
This older catalog material includes research and community reports. It has not all been source-checked in this page update and should not be treated as a dosing recommendation.
Body-store research — trial context
250 or 1,000 mg · Oral · Daily · 6 months
Trial in 54 adults; biomarker context, not an injectable or cosmetic recommendation.
Model details: Glutathione · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Hong 2005: seven fasting male volunteers aged 22–23,50 mg/kg over 10 min IV (meanweight 65.5 kg); rapid parentGSH loss about 10 min. Legacy 0.48 h is not an established generic route half-life. Keep generic relative timing unvalidated until route-specific selection; the 10 min IV measurement is a source observation, not silently adopted for oral orSC dosing.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.48 hours
- Absorption half-life assumed
- 0.12 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- ReducedGSH, oxidizedGSSG and totalGSH must be separated.
- The reviewed IV study subtracts baseline for exposure calculations; it cannot be transplanted to oral/IM/SC use.
- A future dedicated IV model needs infusion input and exact analyte-specific table extraction; do not mistake total GSH for the reduced-GSH peak.
- Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.
Hong 2005: seven fasting male volunteers aged 22–23,50 mg/kg over 10 min IV (meanweight 65.5 kg); rapid parentGSH loss about 10 min. Legacy 0.48 h is not an established generic route half-life.
- Hong et al.2005, glutathione and metabolite PK in normal subjects
50 mg/kg over 10 min IV in seven men; parent/oxidized/total GSH and metabolites measured separately, baseline subtracted for AUC.
glutathione-relative-timing-2026-10 · version 1
Common questions
Is oral glutathione useless?
No. The cited six-month trial found increases in body stores. That does not prove every oral formulation or every cosmetic claim.
Does a larger IV peak mean better detox?
No. A concentration peak does not establish removal of a toxin, symptom improvement or a lasting skin result.
Sources Labels, studies and notes behind this guide
Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interests
- “Detox” is too vague to predict a measurable benefit.
- Oral evidence
- A biomarker response is not proof of visible skin or energy improvement.
- Injection trade-off
- A stronger blood-level peak is not proof of a better outcome.
- 1. Richie et al.: oral glutathione trial
Original abstract inspected: 54 healthy nonsmokers; 250 or 1000 mg/day orally for six months; biomarker endpoint.
- 2. IV glutathione skin-tone trial
Original report search abstract inspected: limited efficacy, declining improvement after stopping; multi-ingredient injectable preparation, not pure glutathione equivalence.
- 3. FDA: injectable glutathione and endotoxin
FDA notice inspected; adverse events and contamination involving supplement-grade material used for injections.
- 4. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.
Hong 2005: seven fasting male volunteers aged 22–23,50 mg/kg over 10 min IV (meanweight 65.5 kg); rapid parentGSH loss about 10 min. Legacy 0.48 h is not an established generic route half-life.
- 5. Hong et al.2005, glutathione and metabolite PK in normal subjects
50 mg/kg over 10 min IV in seven men; parent/oxidized/total GSH and metabolites measured separately, baseline subtracted for AUC.
- 6. Aebi et al.: intravenous glutathione pharmacokinetics
Human high-dose IV study reported mean plasma half-life 14.1 ± 9.2 minutes; dose and route specific. Does not validate the catalog’s simple-model parameters.
Keep reading
Related compounds and examples
Related compounds
KPV
KPV for gut and skin concerns: oral versus injected products, reported dose context and realistic expectations for inflammation claims.
Thymalin
Thymalin for immune support and healthy-aging questions: the reported short course, product differences and what the clinical study can tell you.
VIP (Vasoactive Intestinal Peptide)
VIP nasal spray and peptide uses: CIRS questions, published dose context and how nasal, inhaled and injected formulations differ.